1246765-45-6

Upstream product

• 67-56-1 methanol 
• 42144-78-5 2-chloro-6-ethoxy-pyridine 
• 141-52-6 sodium ethanolate 
• 65515-28-8 methyl 2,6-dichloronicotinate 

Relevant academic research and scientific papers

PYRIDINE DERIVATIVES AND THIER USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES

A compound of formula (Ia), (Ib) or (Ic) wherein: n is 1 or 2; RN is H or Me; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d (if present) are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4a is selected from OH, -NH2, -C(=O)NH2, and -CH2OH; R4b is either H or Me; R5 is either H or Me; A is either (i), where R6a is ether; or (ii),, where X is selected from CH2, NH and O, one of R7a and R7b is selected from CI and ethoxy and the other of R7a and R7b is H.

4, 5-DIHYDRO-LH-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES

Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.